Exelixis, Inc. (EXEL)
NASDAQ: EXEL · Real-Time Price · USD
37.26
+1.04 (2.87%)
At close: Aug 1, 2025, 4:00 PM
37.47
+0.21 (0.56%)
After-hours: Aug 1, 2025, 4:29 PM EDT
CTI BioPharma Employees
Exelixis had 1,147 employees as of December 31, 2024. The number of employees decreased by 163 or -12.44% compared to the previous year.
Employees
1,147
Change (1Y)
-163
Growth (1Y)
-12.44%
Revenue / Employee
$1,944,207
Profits / Employee
$525,107
Market Cap
10.03B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1,147 | -163 | -12.44% |
Dec 31, 2023 | 1,310 | 87 | 7.11% |
Dec 31, 2022 | 1,223 | 269 | 28.20% |
Dec 31, 2021 | 954 | 181 | 23.42% |
Dec 31, 2020 | 773 | 156 | 25.28% |
Dec 31, 2019 | 617 | 133 | 27.48% |
Dec 31, 2018 | 484 | 112 | 30.11% |
Dec 31, 2017 | 372 | 85 | 29.62% |
Dec 31, 2016 | 287 | 172 | 149.57% |
Dec 31, 2015 | 115 | 17 | 17.35% |
Dec 31, 2014 | 98 | -129 | -56.83% |
Dec 31, 2013 | 227 | 53 | 30.46% |
Dec 31, 2012 | 174 | -26 | -13.00% |
Dec 31, 2011 | 200 | -183 | -47.78% |
Dec 31, 2010 | 383 | -293 | -43.34% |
Dec 31, 2009 | 676 | 0 | - |
Dec 31, 2008 | 676 | -59 | -8.03% |
Dec 31, 2007 | 735 | 84 | 12.90% |
Dec 31, 2006 | 651 | 101 | 18.36% |
Dec 31, 2005 | 550 | 33 | 6.38% |
Dec 31, 2004 | 517 | -56 | -9.77% |
Dec 31, 2003 | 573 | 23 | 4.18% |
Dec 31, 2002 | 550 | -21 | -3.68% |
Dec 31, 2001 | 571 | 214 | 59.94% |
Dec 31, 2000 | 357 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
EXEL News
- 2 days ago - Exelixis: Zanzalintinib Sees Mixed Progress, Cabozantinib Grinds Upwards - Seeking Alpha
- 4 days ago - Analyst Surprised By Exelixis Q2 Revenue Miss, Delays STELLAR-304 Readout, Halts STELLAR-305 Phase 3 Plans - Benzinga
- 4 days ago - Exelixis, Inc. (EXEL) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update - Business Wire
- 8 days ago - Exelixis' Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors - Business Wire
- 19 days ago - Exelixis to Release Second Quarter 2025 Financial Results on Monday, July 28, 2025 - Business Wire
- 5 weeks ago - Exelixis: Zanzalintinib MOA Overcomes Competing CRC Regorafenib Treatment - Seeking Alpha
- 5 weeks ago - Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars - Benzinga